Cockrell Group
Long only, deep value, value, growth at reasonable price

Supernus Pharma: An Overlooked, Undervalued Investment Opportunity

Summary & Recommendation

We are initiating on Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) with a positive outlook. The Company has two products, Oxtellar XR™ and Trokendi XR™, for the treatment of epilepsy that were recently FDA approved and has steady uptake in the marketplace. In the U.S. alone, some 2 million people are affected by epilepsy. Globally, epilepsy affects 50 million people. According to data from IMS Health, U.S. sales of antiepilepsy drugs totaled $4 billion in 2011.

Supernus is a Rockville, Maryland-based specialty pharmaceutical company that is focused on the development and commercialization of products for the treatment of central nervous system diseases. The company has recently seen the launch of two products for the treatment of epilepsy. It...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details